Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by VAN DER VOET, G. B.
Right arrow Articles by DE WOLFF, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VAN DER VOET, G. B.
Right arrow Articles by DE WOLFF, F. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

brief-report

ELEVATION OF SERUM ALUMINIUM CONCENTRATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DRUGS CONTAINING ALUMINIUM

G. B. VAN DER VOET*, B. A. C. DIJKMANS1,{dagger}, C. FRANKFORT{dagger} and F. A. DE WOLFF*

*Toxicology Laboratory, University Hospital Leiden, The Netherlands
{dagger}Department of Rheumatology, University Hospital Leiden, The Netherlands

Correspondence to: 1Correspondence to: B. A. C. Dijkmans, Department of Rheumatology, Building 1, C2-Q, University Hospital Leiden, PO Box 9600,2300 RC Leiden, The Netherlands.

In a group of 19 rheumatoid arthritis (RA) patients with normal renal function, serum levels of aluminium (A1S) were monitored during treatment with drugs containing this metal (Al).

The A1S levels during treatment were significantly higher (0.005>p>0.01) than those before treatment, i.e. 19.4 (SEM 2.3)µg/1 and 12.3 (1.7), respectively. This increase in A1S was significantly (0.025>p>0.05) correlated with the pretreatment serum creatinine level (mean value for the whole group 80.5 (SEM 4.7) mol/1) but showed no correlation with the predicted creatinine clearance. Although the increase in A1S during therapy with Al containing drugs is not dramatic in RA patients with normal renal function, the rheumatologist should be aware of the risk of increased A1S concentration in RA patients, especially those with impaired renal function.

KEY WORDS: Renal function, Trace metals, Arthritis, Elderly, Toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.